Compare Abeona Therapeutics Inc (ABEO) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.87. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | JNK | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $98.19 |
52-Week Low | $4.17 | $94.66 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JNK trades at $96.15 with a slight 0.17% daily gain, but technical indicators show a bearish trend with 15 sell signals versus 1 buy. The ETF maintains consistent dividend distributions, with recent payouts around $0.52-$0.53. Market sentiment is cautious amid Federal Reserve uncertainty and inflation concerns, while bond ETF inflows hit record levels according to CNBC on June 25, 2026.
Outlook remains pressured by rising rate hike expectations and high-yield bond vulnerabilities. Risks include Fed policy shifts and economic volatility, but the ETF's yield appeal persists for income-focused investors. Analyst consensus is bearish, with Seeking Alpha rating JNK a SELL on June 15, 2026, citing exhausted tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
